Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction

The MEK inhibitors cobimetinib and trametinib are used in combination with BRAF inhibitors to treat metastatic melanoma but increase rates of hemorrhage relative to BRAF inhibitors alone. Platelets express several members of the MAPK signalling cascade including MEK1 and MEK2 and ERK1 and ERK2 but t...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Platelets
Hlavní autoři: Unsworth, Amanda J., Bye, Alexander P., Kriek, Neline, Sage, Tanya, Osborne, Ashley A., Donaghy, Dillon, Gibbins, Jonathan M.
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2018
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6594423/
https://ncbi.nlm.nih.gov/pubmed/30252580
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/09537104.2018.1514107
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky